Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Non Operating Income (2016 - 2025)

Protalix BioTherapeutics has reported Non Operating Income over the past 14 years, most recently at -$118000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at -$118000.0 for Q4 2025, down 210.28% from a year ago — trailing twelve months through Dec 2025 was -$108000.0 (down 145.57% YoY), and the annual figure for FY2025 was -$108000.0, down 145.57%.
  • Non Operating Income for Q4 2025 was -$118000.0 at Protalix BioTherapeutics, down from $108000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for PLX hit a ceiling of $413000.0 in Q1 2025 and a floor of -$2.3 million in Q3 2021.
  • Median Non Operating Income over the past 5 years was -$429000.0 (2022), compared with a mean of -$513400.0.
  • Biggest five-year swings in Non Operating Income: tumbled 507.37% in 2023 and later surged 235.77% in 2025.
  • Protalix BioTherapeutics' Non Operating Income stood at -$910000.0 in 2021, then increased by 21.43% to -$715000.0 in 2022, then fell by 13.43% to -$811000.0 in 2023, then skyrocketed by 113.19% to $107000.0 in 2024, then crashed by 210.28% to -$118000.0 in 2025.
  • The last three reported values for Non Operating Income were -$118000.0 (Q4 2025), $108000.0 (Q3 2025), and -$511000.0 (Q2 2025) per Business Quant data.